/GNFT.PA

GNFT.PA Stock - Genfit S.A.

Q: What is the analyst price target for GNFT.PA?

Analyst price target information is not currently available for GNFT.PA.

Q: What is GNFT.PA's market cap?

Market capitalization information is not currently available for GNFT.PA.

Healthcare|Biotechnology|PAR

$5.05-0.59%

$0.03 (-0.59%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5.56

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GNFT.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.87

52W High$5.22

52W Low$2.62

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$67.00M	$28.57M	$20.20M	$80.07M	$765,000
Gross Profit	$66.70M	$28.22M	$19.95M	$79.91M	$563,000
Gross Margin	99.6%	98.8%	98.8%	99.8%	73.6%
Operating Income	$3.28M	$-26,580,000	$-27,549,000	$31.82M	$-82,897,000
Net Income	$1.51M	$-28,894,000	$-23,720,000	$67.26M	$-101,221,000
Net Margin	2.2%	-101.2%	-117.5%	84.0%	-13231.5%
EPS	$0.03	$-0.58	$-0.48	$1.51	$-2.60

Company Overview

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Visit Website

Earnings History & Surprises

GNFT.PA

Beat Rate

46%

Last 13 quarters

Avg Surprise

+2.3%

EPS vs Estimate

Beats / Misses

6/7

Last 12 quarters

Latest EPS

$-0.58

Q2 2025

EPS Surprise History

Q3 21

+118.8%

$0.19vs$-1.01

Q2 22

+229.1%

$1.02vs$-0.79

Q3 22

+67.8%

$-0.21vs$-0.65

Q2 23

+67.5%

$-0.27vs$-0.83

Q4 23

-43.0%

$-0.42vs$-0.29

Q2 24

-120.5%

$-0.16vs$0.78

Q4 24

+61.9%

$0.50vs$0.31

Q2 25

-146.8%

$-0.58vs$-0.23

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 22, 2026	—	—	—	—
Q2 2025	Apr 24, 2025	$-0.23	$-0.58	-146.8%	✗ MISS
Q4 2024	Nov 7, 2024	$0.31	$0.50	+61.9%	✓ BEAT
Q2 2024	May 14, 2024	$0.78	$-0.16	-120.5%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.29	$-0.42	-43.0%	✗ MISS
Q2 2023	Apr 14, 2023	$-0.83	$-0.27	+67.5%	✓ BEAT
Q3 2022	Sep 29, 2022	$-0.65	$-0.21	+67.8%	✓ BEAT
Q2 2022	May 11, 2022	$-0.79	$1.02	+229.1%	✓ BEAT
Q3 2021	Sep 30, 2021	$-1.01	$0.19	+118.8%	✓ BEAT
Q2 2021	May 13, 2021	$-1.06	$-1.24	-17.2%	✗ MISS
Q4 2020	Nov 16, 2020	$-1.18	$-1.37	-16.2%	✗ MISS
Q2 2020	May 19, 2020	$-0.94	$-0.36	+61.8%	✓ BEAT
Q4 2019	Oct 1, 2019	$-0.74	$-1.64	-121.6%	✗ MISS
Q2 2019	May 1, 2019	$-0.65	$-1.37	-111.5%	✗ MISS
Q3 2018	Sep 24, 2018	—	$-1.18	—	—
Q2 2018	Apr 27, 2018	—	$-1.06	—	—
Q4 2017	Oct 11, 2017	—	$-0.73	—	—
Q2 2017	May 2, 2017	—	$-0.75	—	—
Q3 2016	Sep 26, 2016	—	$-0.49	—	—
Q2 2016	Apr 26, 2016	—	$-0.34	—	—